ASCO22: Breast cancer research by Meredith Regan, ScD | Dana-Farber Cancer Institute

(1:48)

ASCO22 Metastatic Breast Cancer | Pooja Advani, MBBS, MD | Mayo Clinic

(1:48)

Radiation Therapy Based on LUMINA Trial | Cynthia Ma, MD, PhD | ASCO22 Breast Cancer Updates

(2:17)

ASCO22 Metastatic Breast Cancer Updates | Sramila Aithal, MD | US Oncology

(1:19)

ASCO22 Metastatic Breast Cancer Updates | Lee Schwartzberg, MD | Renown Institute for Cancer

(2:2)

ASCO22: Marla Lipsyc-Sharf, MD on ctDNA in breast cancer | Dana-Farber Cancer Institute

(1:43)

ASCO22 Metastatic Breast Cancer Updates | Anthony Elias, MD | University of Colorado

(6:41)

ASCO22 Early Stage Breast Cancer Updates | Aixa Soyano, MD| Moffitt Cancer Center

(3:20)

DESTINY-Breast04 and Other Key Breast Cancer Studies at ASCO22

(31:4)

Effectiveness of TDXD vs. Sacituzumab for ER+ Breast Cancer | Jane Meisel, MD | ASCO22 Updates

(1:22)

ASCO22 Early-Stage Breast Cancer Updates | Rebecca Shatsky, MD | University of California San Diego

(3:47)

CARG Score Chemotherapy Options ABCSG 18 Trial | Cynthia Ma, MD, PhD | ASCO22 Breast Cancer Updates

(5:58)

ASCO22: Novel Therapies in Breast Cancer

(12:5)

Drs. Bardia, Hurvitz, \u0026 Spring talk #BreastCancer during #ASCO22 - https://bit.ly/3tVN82X

(57:25)

Harold Burstein, MD, PhD on key advances from ASCO 2022

(3:49)

Harold Burstein, MD, PhD on advances in breast cancer research from ASCO 2022

(4:9)

ASCO 2022: Metastatic Breast Cancer Drug Therapy Recap

(7:36)

Antibody Drug Conjugates in Metastatic Breast Cancer | Sramila Aithal, MD | ESMO22 Pennsylvania

(1:45)

DESTINY-04: HER2 1+/FISH- Metastatic Breast Cancer TDXD Treatment | Jane Meisel, MD | ASCO22 Updates

(1:10)

Is HER2-low a distinct subtype of breast cancer?

(1:36)